Doxifluridine-induced neurotoxicity with normal dihydropyrimidine dehydrogenase activity.
Kim
Dong Wook
DW
Department of Neurology, Neuroscience Research Institute, Seoul National University College of Medicine, Korea.
Kim
Han-Joon
HJ
Kim
Dong-Eog
DE
Roh
Jae-Kyu
JK
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001711:Biotransformation; D002529:Cerebellar Nuclei / Q000187:drug effects* / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003131:Combined Modality Therapy; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000097:blood*; D004401:Dysarthria / Q000139:chemically induced*; D005467:Floxuridine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D020233:Gait Disorders, Neurologic / Q000139:chemically induced*; D005743:Gastrectomy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009759:Nystagmus, Pathologic / Q000139:chemically induced; D010292:Paresthesia / Q000139:chemically induced; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000601:surgery; D014202:Tremor / Q000139:chemically induced
D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; D042943:Dihydrouracil Dehydrogenase (NADP); C025034:doxifluridine